Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  CVS Health Corp    CVS

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CVS Caremark 4th-Quarter Profit Rose 2.6% Amid Continued Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/06/2013 | 01:52pm CEST
   By Tess Stynes 
 

CVS Caremark Corp.'s (>> CVS Caremark Corporation) fourth-quarter earnings rose 2.6% as the company reported revenue growth in its pharmacy-services and retail drugstore operations.

For the year, the company raised its forecast for per-share adjusted earnings from continuing operations by two cents and now expects $3.86 to $4.

CVS's retail pharmacy business gained customers last year in the wake of a contract dispute between rival Walgreen Co.'s (>> Walgreen Company) and pharmacy-benefits manager Express Scripts Holding Co. (>> Express Scripts Holding Co) that has since been resolved.

A wave of major generic drugs introductions is having a mixed effect on the industry. Though the copycat drugs carry higher margins than branded products, they command lower prices, hurting sales revenue.

CVS Caremark reported a profit of $1.13 billion, or 90 cents a share, up from $1.1 billion, or 81 cents a share, a year earlier. Excluding debt-extinguishment losses, acquisition-related charges and other items, adjusted earnings from continuing operations were $1.14. Revenue increased 11% to $31.39 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.10 on revenue of $31.13 billion.

Revenue in the larger pharmacy-services business climbed 17% to $18.6 billion, reflecting new client starts, higher prices and growth of its Medicare Part D program. Pharmacy network claims processed rose 6.5%.

On the retail side, revenue increased 5.1% to $16.3 billion. Same-store sales were up 4% from a year earlier, as pharmacy same-store sales also improved by 4%. Same-store sales in the front end of the store grew 3.9%.

Shares closed Tuesday at $51.72 and were inactive premarket.

Write to Tess Stynes at tess.stynes@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CVS HEALTH CORP
03/24 CVS HEALTH : Offers Private Sector Solutions to America's Health Care Challenges
03/23 CVS HEALTH : Takes Next Step in Five-Year Commitment to Deliver the First Tobacc..
03/23 CVS HEALTH : PBM Clients Achieved Lowest Prescription Drug Trend in Four Years, ..
03/23 CVS HEALTH : Launches Reduced Rx Savings Program to Give Patients Access to More..
03/23 CVS HEALTH : University of Pittsburgh School of Pharmacy and Pittsburgh Public S..
03/23 INSIDER TRADING ACTIVITY CVS HEALTH : CVS) – EVP Sold 23,849 shares of St..
03/21 INSIDER TRADING ACTIVITY CVS HEALTH : CVS) – EVP Sold 6,029 shares of Sto..
03/17 CVS : Driving Affordable Solutions: Reduced Rx Prescription Savings Program
03/16 CVS HEALTH : Oak Paper Products Company, Inc. Appoints New Board Of Directors
03/16 CVS HEALTH : Expands Access to Opioid Overdose-Reversal Drug at CVS Pharmacy loc..
More news
Sector news : Drug Retailers - NEC
02/28 Valeant predicts tough 2017 with revenue to decline
02/16DJRetail CEOs Meet With Trump Over Border Tax Concerns -- Update
02/15DJRetail CEOs Meet With Trump Over Border Tax Concerns
02/14DJEXPRESS SCRIPTS : Revenue Falls
02/14 Exclusive - Trump to meet with retail CEOs on taxes, infrastructure
More sector news : Drug Retailers - NEC
News from SeekingAlpha
03/25 GNC : Updated Short Interest And Goldman Sachs' $5 Price Target
03/24 RETIREES : How To Protect The Principal Of Your Dividend Portfolio
03/21 AMERICAN COLLEGE OF CARDIOLOGY : No Repatha Of Glory
03/21 Selling Or Trimming Reasons Within My 86 Stock Portfolio
03/20 10 Dividend Growth Stocks For March 2017
Advertisement
Financials ($)
Sales 2017 184 272 M
EBIT 2017 10 737 M
Net income 2017 5 639 M
Debt 2017 24 998 M
Yield 2017 2,44%
P/E ratio 2017 14,84
P/E ratio 2018 13,28
EV / Sales 2017 0,57x
EV / Sales 2018 0,54x
Capitalization 80 528 M
More Financials
Chart CVS HEALTH CORP
Duration : Period :
CVS Health Corp Technical Analysis Chart | CVS | US1266501006 | 4-Traders
Full-screen chart
Technical analysis trends CVS HEALTH CORP
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 86,5 $
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Non-Executive Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
David M. Denton Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CVS HEALTH CORP-0.51%80 528
WALGREENS BOOTS ALLIAN..0.97%90 195
EXPRESS SCRIPTS HOLDIN..-6.09%38 780
MCKESSON CORPORATION5.73%31 490
CARDINAL HEALTH INC14.28%25 946
AMERISOURCEBERGEN CORP..11.88%19 008
More Results